Published in Br J Cancer on March 06, 2007
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer (2012) 1.23
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol (2007) 0.94
Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities. Br J Cancer (2008) 0.93
Physical state and viral load as predictive biomarkersfor persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study. Am J Cancer Res (2012) 0.86
Human papillomavirus type 16 viral load measurement as a predictor of infection clearance. J Gen Virol (2013) 0.86
Development of a bead-based multiplex genotyping method for diagnostic characterization of HPV infection. PLoS One (2012) 0.85
Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know. Eur Arch Otorhinolaryngol (2012) 0.85
Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types. J Virol (2013) 0.85
Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer (2011) 0.83
Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach. PLoS One (2012) 0.83
Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer (2015) 0.82
Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One (2013) 0.81
Mucosal immunity in the female genital tract, HIV/AIDS. Biomed Res Int (2014) 0.81
Methylation of human papillomavirus Type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR. J Clin Microbiol (2013) 0.80
Eight nucleotide substitutions inhibit splicing to HPV-16 3'-splice site SA3358 and reduce the efficiency by which HPV-16 increases the life span of primary human keratinocytes. PLoS One (2013) 0.79
A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test. J Virol Methods (2011) 0.79
HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer (2012) 0.79
Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol (2009) 0.79
Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study. BMC Infect Dis (2014) 0.79
Performance of a polymer-based DNA chip platform in detection and genotyping of human papillomavirus in clinical samples. J Clin Microbiol (2009) 0.75
The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control (2016) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61
A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol (1997) 6.09
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer (2004) 3.03
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst (2005) 2.47
Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer (2001) 2.26
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96
The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol (2004) 1.55
Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer (2005) 1.55
Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA (1992) 1.51
Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev (2006) 1.47
Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer (2003) 1.41
Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer (2005) 1.37
High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev (2001) 1.37
Permutational distribution of the log-rank statistic under random censorship with applications to carcinogenicity assays. Biometrics (1998) 1.05
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet (1999) 4.24
The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer (1995) 3.29
The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol (2004) 2.63
Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene (2006) 2.56
Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet (2001) 2.35
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer (2004) 2.33
Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer (2002) 2.25
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect (2002) 2.05
Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol (2006) 2.02
Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer (2006) 1.83
Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol (2000) 1.83
Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer (2002) 1.83
Papillomavirus infection in rural women in southern India. Br J Cancer (2005) 1.79
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol (2013) 1.77
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol (2000) 1.69
CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol (2004) 1.63
Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer (2006) 1.62
Apoptosis in myocardial ischaemia and infarction. J Clin Pathol (2002) 1.59
Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations? J Clin Microbiol (2000) 1.58
Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet (2001) 1.56
The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol (2004) 1.55
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer (2012) 1.53
Mutations in the T (brachyury) gene cause a novel syndrome consisting of sacral agenesis, abnormal ossification of the vertebral bodies and a persistent notochordal canal. J Med Genet (2013) 1.51
C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest (2004) 1.50
HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer (2009) 1.50
Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol (2011) 1.47
Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol (2006) 1.46
Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer (2006) 1.43
A CD56-negative case of blastic natural killer-cell lymphoma (agranular CD4+/CD56+ haematodermic neoplasm). Br J Dermatol (2004) 1.43
[Condylomata acuminata: a rare symptom of ubiquitous human papilloma virus and not a sign of risky sex behavior]. Ned Tijdschr Geneeskd (1999) 1.40
Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol (2002) 1.36
Validation of high-risk HPV tests for primary cervical screening. J Clin Virol (2009) 1.35
[Vaccines against human papillomavirus (HPV); between registration and implementation]. Ned Tijdschr Geneeskd (2008) 1.34
Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer (2012) 1.34
[Flat penile lesions in the sexual transmission of human papillomavirus]. Ned Tijdschr Geneeskd (2008) 1.32
Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer (2007) 1.32
A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol (2005) 1.31
Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol (2014) 1.30
Evaluating an educational intervention to improve the treatment of asthma in four European countries. Drug Education Project Group. Am J Respir Crit Care Med (1999) 1.28
Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol (2008) 1.28
Effects of stressful daily events on mood states: relationship to global perceived stress. J Pers Soc Psychol (1998) 1.28
Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology (2006) 1.28
Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. J Hosp Infect (2005) 1.26
Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol (2003) 1.25
Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol (2006) 1.24
Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. J Immunol (2001) 1.20
Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol (2005) 1.20
HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol (1995) 1.18
Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer (2008) 1.17
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer (2008) 1.16
Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer (2001) 1.15
14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology (2000) 1.14